Profile data is unavailable for this security.
About the company
Paradigm Biopharmaceuticals Limited is a late-stage drug development company engaged in discovering, developing, and delivering pharmaceutical therapies. It is focused on the development of injectable pentosan polysulfate sodium (iPPS/PPS) for the treatment of osteoarthritis (OA) and mucopolysaccharidosis (MPS). PPS is a semi-synthetic drug manufactured from the wood chips of European beech trees. Extracted glucurono-xylans are sulfated to produce a negatively charged product that mimics glycosaminoglycans. It develops PPS under the brand name Zilosul. Other indications under investigation for PPS include the treatment of joint function, mobility, and pain in patients with mucopolysaccharidoses; treating alphavirus-induced arthralgia; chronic heart failure; acute respiratory distress syndrome; and allergic respiratory conditions. It is also advancing early formulation development for Pentacoxib, an oral combination of PPS and a COX-2 inhibitor targeting patients with earlier-stage OA.
- Revenue in AUD (TTM)7.11m
- Net income in AUD-18.77m
- Incorporated2014
- Employees--
- LocationParadigm Biopharmaceuticals LtdLevel 15, 500 Collins StMELBOURNE 3000AustraliaAUS
- Phone+61 39629-5566
- Fax+61 39629-5466
- Websitehttps://paradigmbiopharma.com/
More ▼
Mergers & acquisitions
| Acquired company | PAR:ASX since announced | Transaction value |
|---|---|---|
| ProteoBioactives Pty Ltd | -3.13% | 326.00k |
Data delayed at least 20 minutes, as of Feb 11 2026 05:10 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rhythm Biosciences Ltd | 3.33m | -3.83m | 73.59m | -- | -- | 98.99 | -- | 22.13 | -0.0134 | -0.0134 | 0.0124 | 0.0023 | 1.53 | 98.79 | 67.11 | -- | -176.04 | -146.24 | -469.96 | -197.40 | -10.44 | 22.48 | -115.14 | -287.42 | 0.8046 | -53.89 | 0.6266 | -- | 90.87 | 135.14 | 44.15 | -- | -12.61 | -- |
| Prescient Therapeutics Ltd | 225.61k | -7.32m | 73.61m | 3.00 | -- | 4.95 | -- | 326.25 | -0.0091 | -0.0091 | 0.0003 | 0.0141 | 0.0129 | -- | 0.9582 | -- | -41.90 | -31.70 | -49.69 | -34.33 | -- | -- | -3,245.66 | -2,146.75 | -- | -590.48 | 0.00 | -- | -67.19 | 26.24 | 11.11 | -- | -- | -- |
| Proteomics International LaboratoriesLtd | 3.31m | -8.11m | 75.16m | -- | -- | 5.65 | -- | 22.69 | -0.0605 | -0.0605 | 0.0247 | 0.0805 | 0.2582 | -- | 12.02 | -- | -63.57 | -63.62 | -68.88 | -71.91 | -- | -- | -246.18 | -222.10 | -- | -- | 0.021 | -- | 1.34 | 15.81 | -27.27 | -- | -54.88 | -- |
| Imugene Ltd | 0.00 | -69.02m | 83.59m | 0.00 | -- | 1.27 | -- | -- | -0.3161 | -0.3161 | 0.00 | 0.205 | 0.00 | -- | -- | -- | -58.75 | -48.72 | -75.21 | -53.73 | -- | -- | -- | -- | -- | -- | 0.1913 | -- | -- | -- | 53.89 | -- | 38.40 | -- |
| Alterity Therapeutics Ltd | 446.29k | -12.15m | 87.00m | 9.00 | -- | 1.72 | -- | 194.95 | -0.002 | -0.002 | 0.00007 | 0.0047 | 0.0137 | -- | 5,578.63 | 49,587.78 | -37.23 | -49.00 | -43.12 | -57.35 | -- | -- | -2,721.96 | -9,708.51 | -- | -211.82 | 0.0037 | -- | 66.27 | 91.97 | 36.48 | -- | -- | -- |
| Cynata Therapeutics Ltd | 227.70k | -9.39m | 91.42m | 0.00 | -- | 14.54 | -- | 401.49 | -0.0453 | -0.0453 | 0.0011 | 0.0265 | 0.0292 | -- | 2.16 | -- | -120.50 | -48.36 | -142.29 | -53.09 | -- | -- | -4,124.10 | -576.20 | -- | -1,268.00 | 0.00 | -- | -45.49 | 28.12 | 3.63 | -- | -- | -- |
| Bioxyne Ltd | 28.43m | 4.90m | 100.80m | 16.00 | 19.40 | 7.85 | 17.72 | 3.55 | 0.0023 | 0.0023 | 0.0132 | 0.0057 | 2.16 | 6.30 | 17.06 | -- | 37.31 | -28.17 | 55.76 | -38.16 | 36.32 | 35.97 | 17.24 | -24.14 | 1.90 | -- | 0.1125 | -- | 204.87 | 65.94 | 138.29 | -- | 127.89 | -- |
| Tetratherix Ltd | 1.14m | -9.43m | 103.00m | -- | -- | 7.00 | -- | 90.14 | -0.1873 | -0.1873 | 0.0227 | 0.5414 | 0.0688 | -- | 2.22 | -- | -56.71 | -- | -76.72 | -- | -172.06 | -- | -824.89 | -- | -- | -98.75 | 0.0697 | -- | 32.30 | -- | -269.05 | -- | -- | -- |
| LTR Pharma Ltd | 2.10m | -5.59m | 107.22m | -- | -- | 3.39 | -- | 50.97 | -0.0333 | -0.0333 | 0.0126 | 0.1741 | 0.1183 | -- | 8.22 | -- | -31.44 | -- | -32.47 | -- | -- | -- | -265.90 | -- | 45.76 | -62.54 | 0.00 | -- | 4,164.38 | -- | 19.57 | -- | -- | -- |
| Island Pharmaceuticals Ltd | 58.80k | -3.92m | 111.66m | -- | -- | 13.69 | -- | 1,898.92 | -0.0224 | -0.0224 | 0.0003 | 0.0303 | 0.0117 | -- | 0.1099 | -- | -77.95 | -72.12 | -90.37 | -81.53 | -- | -- | -6,666.91 | -19,239.15 | -- | -162.89 | 0.00 | -- | 1,148.41 | -- | -36.86 | -- | -- | -- |
| Arovella Therapeutics Ltd | 525.53k | -7.51m | 118.92m | 14.00 | -- | 5.86 | -- | 226.28 | -0.0067 | -0.0067 | 0.0005 | 0.0169 | 0.0301 | -- | -- | -- | -43.05 | -75.94 | -47.90 | -90.89 | -- | -- | -1,428.87 | -2,386.13 | -- | -- | 0.00 | -- | 237.44 | -1.82 | 14.14 | -- | 1.23 | -- |
| Paradigm Biopharmaceuticals Ltd | 7.11m | -18.77m | 134.44m | -- | -- | 5.70 | -- | 18.92 | -0.047 | -0.047 | 0.0183 | 0.0544 | 0.2684 | -- | 1.14 | -- | -70.91 | -67.55 | -80.99 | -75.98 | 99.71 | 99.24 | -264.18 | -527.01 | -- | -9,722.29 | 0.0003 | -- | 10.29 | 8.87 | 68.04 | -- | -- | -- |
| Actinogen Medical Ltd | 685.26k | -14.73m | 148.86m | -- | -- | 7.45 | -- | 217.23 | -0.005 | -0.005 | 0.0002 | 0.0058 | 0.0299 | -- | 0.0907 | -- | -64.34 | -53.87 | -76.58 | -59.25 | -- | -- | -2,149.88 | -3,680.96 | -- | -231.81 | 0.1511 | -- | 135.46 | 48.76 | -12.94 | -- | 10.81 | -- |
| Nyrada Inc | 2.56m | -4.85m | 198.41m | -- | -- | 47.76 | -- | 77.54 | -0.0243 | -0.0243 | 0.0128 | 0.017 | 0.4566 | -- | -- | -- | -86.47 | -48.87 | -112.02 | -53.88 | -- | -- | -189.37 | -195.83 | -- | -- | 0.00 | -- | -24.81 | 18.93 | -248.28 | -- | -- | -- |
Data as of Feb 11 2026. Currency figures normalised to Paradigm Biopharmaceuticals Ltd's reporting currency: Australian Dollar AUD
10.35%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Allianz Global Investors GmbHas of 17 May 2024 | 21.31m | 4.97% |
| RBC Global Asset Management (Asia) Ltd.as of 31 Dec 2025 | 11.52m | 2.69% |
| Allianz Global Investors Asia Pacific Ltd.as of 30 Sep 2025 | 11.00m | 2.57% |
| Dimensional Fund Advisors LPas of 08 Jan 2026 | 266.11k | 0.06% |
| DFA Australia Ltd.as of 31 Dec 2025 | 253.27k | 0.06% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
